中国神经再生研究(英文版) ›› 2017, Vol. 12 ›› Issue (4): 558-561.doi: 10.4103/1673-5374.205085

• 综述:脑损伤修复保护与再生 • 上一篇    下一篇

内皮祖细胞是脑内出血的治疗选择

  

  • 收稿日期:2017-03-07 出版日期:2017-04-15 发布日期:2017-04-15
  • 基金资助:

    此项研究由西班牙经济与竞争力部(SAF2014-56336)、萨洛德卡洛斯三世研究所(PI13 / 00292&PI14 / 01879)、西班牙脑血管病研究网(RETICS INVICTUS; RD12 / 0014)、Xunta德加利西亚(教育部,GRC2014 / 027)及欧盟计划FEDER共同赞助

Endothelial progenitor cells as a therapeutic option in intracerebral hemorrhag

Juan Pías-Peleteiro, Francisco Campos, José Castillo, Tomás Sobrino   

  1. Clinical Neurosciences Research Laboratory, Department of Neurology, Stroke Unit, University Clinical Hospital, Universidade de Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
  • Received:2017-03-07 Online:2017-04-15 Published:2017-04-15
  • Contact: Tomás Sobrino, Ph.D. or José Castillo, Ph.D., tomas.sobrino.moreiras@sergas.es or jose.castillo.sanchez@sergas.es.
  • Supported by:

    This study has been partially supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2014-56336), the Instituto de Salud Carlos III (PI13/00292 & PI14/01879), the Spanish Research Network on Cerebrovascular Diseases (RETICS INVICTUS; RD12/0014), the Xunta de Galicia (Department of Education, GRC2014/027), and the European Union program FEDER. Furthermore, F. Campos (CP14/00154) and TS (CP12/03121) are recipients of a research contract from Miguel Servet Program of Instituto de Salud Carlos III. The funders had no role in the review design, data collection and analysis, decision to publish, or preparation of the manuscript.

摘要:

 

脑内出血是脑卒中发病率最高的一种亚型。总的来说,脑内出血是发达国家人口死亡和残疾的主要原因,其发病率随着老年人口的增长而增高。目前手术方法只对有限适应症有效,并仅代表较少部分的临床相关生存优势。尽管这是一类最严重的脑血管疾病,但脑内出血却没有具体的药物治疗手段。

目前有充分的证据显示,循环内皮祖细胞(EPCs)在内皮化重塑,血管生成和血管发生中的重要作用。事实上,已有报道描述了脑内出血患者具有增加的循环EPC水平。本文最新研究发现EPC水平与良好的神经和功能结果相关,并可减少患有急性脑内出血患者的出血残留体积。EPC支持的血管生成过程将是神经修复中的早期和关键步骤,因为它可能与随后的神经发生相关。因此,基于外源性补充或内源性刺激的EPC治疗可能是脑内出血中的可行治疗选择,主要通过血管生成和神经源性机制起作用。

Abstract:

Intracerebral hemorrhage (ICH) is the most severe cerebrovascular disease, which represents a leading cause of death and disability in developed countries. However, therapeutic options are limited, so is mandatory to investigate repairing processes after stroke in order to develop new therapeutic strategies able to promote brain repair processes. Therapeutic angiogenesis and vasculogenesis hold promise to improve outcome of ICH patients. In this regard, circulating endothelial progenitor cells (EPCs) have recently been suggested to be a marker of vascular risk and endothelial function. Moreover, EPC levels have been associated with good neurological and functional outcome as well as reduced residual hematoma volume in ICH patients. Finally, experimental and clinical studies indicate that EPC might mediate endothelial cell regeneration and neovascularization. Therefore, EPC-based therapy could be an excellent therapeutic option in ICH. In this mini-review, we discuss the present status of knowledge about the possible therapeutic role of EPCs in ICH, molecular mechanisms, and the future perspectives and strategies for their use in clinical practice.

Key words: cellular therapy, endothelial progenitor cells, growth factors, intracerebral hemorrhage, neurorepair, outcome